Information Provided By: 
Fly News Breaks for October 6, 2015
TMO, ILMN
Oct 6, 2015 | 07:39 EDT
After Illumina (ILMN) preannounced lower than expected revenue, Wells Fargo says that the company continues to have a monopoly in high-throughput sequencing, while it continues to be the only pure-play stock of meaningful market cap offering broad non-therapeutic exposure to "the personalized medicine revolution." Wells thinks that Thermo Fisher (TMO) could be gaining share in low-throughput sequencing, but it does not believe that this business is the main value driver for Illumina. Wells keeps an Outperform rating on Illumina.
News For ILMN;TMO From the Last 2 Days
TMO
Apr 25, 2024 | 08:51 EDT
Deutsche Bank raised the firm's price target on Thermo Fisher to $610 from $600 and keeps a Buy rating on the shares post the Q1 report. The analyst says a solid operational performance drove a strong start to 2024.
TMO
Apr 25, 2024 | 08:29 EDT
TMO
Apr 25, 2024 | 07:32 EDT
TMO
Apr 25, 2024 | 07:03 EDT
TMO
Apr 25, 2024 | 06:31 EDT
TMO
Apr 25, 2024 | 05:12 EDT
Barclays analyst Luke Sergott raised the firm's price target on Thermo Fisher to $615 from $590 and keeps an Equal Weight rating on the shares. The company reported a beat across the board, says the analyst, who sees the business stabilizing.
TMO
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
TMO
Apr 24, 2024 | 06:11 EDT
TMO
Apr 24, 2024 | 06:09 EDT
TMO
Apr 24, 2024 | 06:02 EDT
